Probiotics-related Clostridium butyricum bacteraemia after COVID-19, confirmed by whole-genome sequencing.
BMJ Case Rep
; 17(8)2024 Aug 03.
Article
em En
| MEDLINE
| ID: mdl-39097326
ABSTRACT
A man in his 70s was admitted to an intensive care unit with severe COVID-19 and treated with dexamethasone and tocilizumab. After recovery from COVID-19, he developed Clostridium butyricum bacteraemia and non-occlusive mesenteric ischaemia, with fatal outcome. He had been prescribed C. butyricum MIYAIRI 588 fine granules as probiotics for a month. The genome sequences of the C. butyricum isolate from the blood culture and C. butyricum MIYAIRI 588 fine granules were identical by single nucleotide polymorphism analysis. This is the first case of definitive probiotics-related C. butyricum bacteraemia after treatment of severe COVID-19.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bacteriemia
/
Probióticos
/
Clostridium butyricum
/
Sequenciamento Completo do Genoma
/
COVID-19
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
BMJ Case Rep
/
BMJ case reports
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Japão